Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine and naproxen to prevent granulocyte colony-stimulating factor–induced pain in cancer patients
IRCT20190922044848N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Nov 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of loratadine and naproxen in breast cancer, multiple myeloma (MM), Hodgkin lymphoma (HL) and 5 more, sponsored by Alborz University of Medical Sciences. Started Nov 2018; status: completed.
02
Drugs
loratadinenaproxen
03
Conditions
breast cancermultiple myeloma (MM)Hodgkin lymphoma (HL)follicular lymphoma (FL)Non-Hodgkin Lymphomas excluding Follicular Lymphoma
Beyond the preview
Go deeper on IRCT20190922044848N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190922044848N1.